Non-alcoholic fatty liver disease's prevalence and impact on alanine aminotransferase associated with metabolic syndrome in the Chinese

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 4, 2011, Pages 722-730

  Hou, Xu hong ^a   Zhu, Yun xia ^a   Lu, Hui juan ^a   Chen, Hui fen ^b   Li, Qiang ^c   Jiang, Shan ^a   Xiang, Kun san ^a   Jia, Wei ping ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^b Shanghai Anting Community Health Center   (China)

^c Shanghai   (China)

Author keywords

Cross sectional survey; Metabolic syndrome; Non alcoholic fatty liver disease; Serum alanine aminotransferase

Indexed keywords

ALANINE AMINOTRANSFERASE; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ARTICLE; CHINESE; CIGARETTE SMOKING; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ECHOGRAPHY; FEMALE; HUMAN; HYPERGLYCEMIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL;

EID: 79952838742     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06509.x     Document Type: Article

References (43)

1. Marchesini G, Brizi M, Bianchi G etal. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-50.
2. Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann. Hepatol. 2009; 8 (Suppl. 1): S4-8.
3. Gu D, Reynolds K, Wu X etal. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 2005; 365: 1398-405.
4. Wang Y, Mi J, Shan XY, Wang QJ, Ge KY. Is China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in China. Int. J. Obes. (Lond) 2007; 31: 177-88.
5. Yang W, Lu J, Weng J etal. Prevalence of diabetes among men and women in China. N. Engl. J. Med. 2010; 362: 1090-101.
6. Jia WP, Pang C, Chen L etal. Epidemiological characteristics of diabetes mellitus and impaired glucose regulation in a Chinese adult population: the Shanghai diabetes studies, a cross-sectional 3-year follow-up study in Shanghai urban communities. Diabetologia 2007; 50: 286-92.
7. Hou X, Jia W, Bao Y etal. Risk factors for overweight and obesity, and changes in body mass index of Chinese adults in Shanghai. BMC Public Health 2008; 8: 389.
8. Fan JG, Zhu J, Li XJ etal. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J. Hepatol. 2005; 43: 508-14.
9. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003; 37: 1202-19.
10. Kotronen A, Westerbacka J, Bergholm R, Pietilainen KH, Yki-Jarvinen H. Liver fat in the metabolic syndrome. J. Clin. Endocrinol. Metab. 2007; 92: 3490-7.
11. Zeng MD, Fan JG, Lu LG etal. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases. J. Dig. Dis. 2008; 9: 108-12.
12. Wannamethee SG, Shaper AG, Lennon L, Whincup PH. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 2005; 28: 2913-18.
13. Jeong SK, Nam HS, Rhee JA, Shin JH, Kim JM, Cho KH. Metabolic syndrome and ALT: a community study in adult Koreans. Int. J. Obes. Relat. Metab. Disord. 2004; 28: 1033-8.
14. Ekstedt M, Franzen LE, Mathiesen UL etal. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-73.
15. Prati D, Colli A, Porretti L. Serum aminotransferase activity and mortality risk. Hepatology 2008; 48: 687-8.
16. Lee TH, Kim WR, Benson JT, Therneau TM, Melton LJ 3rd. Serum aminotransferase activity and mortality risk in a United States community. Hepatology 2008; 47: 880-7.
17. Patel DA, Srinivasan SR, Xu JH, Chen W, Berenson GS. Persistent elevation of liver function enzymes within the reference range is associated with increased cardiovascular risk in young adults: the Bogalusa heart study. Metabolism 2007; 56: 792-8.
18. Schindhelm RK, Dekker JM, Nijpels G etal. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the hoorn study. Atherosclerosis 2007; 191: 391-6.
19. Kim SK, Kim DJ, Kim SH etal. Normal range of alanine aminotransferase concentration is associated with carotid atherosclerosis. Diabetes Res. Clin. Pract. 2010; 88: 111-16.
20. Bao Y, Ma X, Li H etal. Glycated haemoglobin A1c for diagnosing diabetes in Chinese population: cross sectional epidemiological survey. BMJ 2010; 340: c2249.
21. Fukushima M, Taniguchi A, Sakai M etal. Homeostasis model assessment as a clinical index of insulin resistance. Comparison with the minimal model analysis. Diabetes Care 1999; 22: 1911-12.
22. Yajima Y, Ohta K, Narui T etal. Ultrasonographical diagnosis of fatty liver: significance of the liver-kidney contrast. Tohoku J. Exp. Med. 1983; 139: 43-50.
23. Prati D, Taioli E, Zanella A etal. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann. Intern. Med. 2002; 137: 1-10.
24. Chinese guidelines on prevention and treatment of dyslipidemia in adults. Zhonghua Xin Xue Guan Bing Za Zhi 2007; 35: 390-419.
25. Guidelines Subcommittee. 1999 world health organization-international society of hypertension guidelines for the management of hypertension. J. Hypertens. 1999; 17: 151-83.
26. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 1998; 15: 539-53.
27. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. World Health Organ. Tech. Rep. Ser. 2000; 894: 1-253.
28. Park SH, Jeon WK, Kim SH etal. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J. Gastroenterol. Hepatol. 2006; 21: 138-43.
29. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn. J. Med. 1988; 27: 142-9.
30. Jimba S, Nakagami T, Takahashi M etal. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet. Med. 2005; 22: 1141-5.
31. Zhou YJ, Li YY, Nie YQ etal. Prevalence of fatty liver disease and its risk factors in the population of South China. World J. Gastroenterol. 2007; 13: 6419-24.
32. Saito T, Nishise Y, Makino N etal. Impact of metabolic syndrome on elevated serum alanine aminotransferase levels in the Japanese population. Metabolism 2009; 58: 1067-75.
33. Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabet. Med. 2007; 24: 1-6.
34. Kashyap SR, Diab DL, Baker AR etal. Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort. Obesity 2009; 17: 1696-701.
35. Sazonov V, Beetsch J, Phatak H, Wentworth C, Evans M. Association between dyslipidemia and vascular events in patients treated with statins: report from the UK general practice research database. Atherosclerosis 2010; 208: 210-16.
36. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am. J. Cardiol. 1996; 77: 1179-84.
37. Juurinen L, Tiikkainen M, Hakkinen AM, Hakkarainen A, Yki-Jarvinen H. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 2007; 292: E829-35.
38. Sattar N, McConnachie A, Ford I etal. Serial metabolic measurements and conversion to type 2 diabetes in the west of Scotland coronary prevention study: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor. Diabetes 2007; 56: 984-91.
39. Sattar N, Scherbakova O, Ford I etal. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes 2004; 53: 2855-60.
40. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99-112.
41. Saadeh S, Younossi ZM, Remer EM etal. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-50.
42. Mofrad P, Contos MJ, Haque M etal. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 1286-92.
43. Wong VW, Wong GL, Tsang SW etal. Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels. Aliment. Pharmacol. Ther. 2009; 29: 387-96.